Why not turn on the next level of cardiac resynchronization therapy with MultiPoint™ Pacing and SyncAV™ CRT technology? See how they work. #NextLevelCRT
Learn more and Important Safety Information:
bit.ly/2LDF7qf
CardiacDevices retweeted
MITRA-FR: no difference in death or rehospitalization for HF in patients with severe secondary MR treated with Mitraclip. Will we continue to perform this procedure? #ESCCongress @escardio
CardiacDevices retweeted
DR. Rioufil-FUTURE Trial: No difference in Primary endpoint death, MI, stroke in FFR guided vs Angio guided strategy in stable angina. Interestingly high all cause death in FFR group driven by complex coronary anatomy! #ESCCongress – at Munich, Germany
CardiacDevices retweeted
MARINER: Outpatient rivaroxaban for six weeks after discharge from the hospital had no significant effect on the risk of VTE as compared with placebo. nej.md/2K4EHsc #ESCCongress #VisualAbstract
Major findings of APAF-CRT trial presented at #ESCCongress by dr Brignole: patients with permanent AF and narrow QRS undergoing CRT plus AV junctional ablation benefit significantly in terms of reduction of death for HF, hospitalization for HF and worsening HF.
CardiacDevices retweeted
Aspirin, for decades, was regarded as the "go to" primary prevention drug vs heart disease. Here the 1st of 2 randomized trials today to question that #ESCCongress thelancet.com/journals/lance… @TheLancet
CardiacDevices retweeted
SCOT HEART: Patients with chest pain assigned to coronary CT angiography have lower rate of CHD death or nonfatal MI at five years than those who didn’t receive CTA. nej.md/2OqnL2y #ESCCongress
CardiacDevices retweeted
POET Trial: Changing to oral antibiotic treatment in stabilized patients with left-sided endocarditis noninferior to continued IV antibiotic tx. nej.md/2LwyRFD #ESCCongress
CardiacDevices retweeted
COMMANDER HF Trial: In pts w/ recent worsening HF w/ red. EF & CAD but not AF, Riva 2.5mg bid did not sig. red. primary MACE endpt or the 2dary comp. of CV death or rehosp for worsening HF. Sig. incr. major bld.
Slide deck here:
clinicaltrialresults.org/Sli…
#ESCCongress
CardiacDevices retweeted
New algorithms on use of DAPT in ACD undergoing revascularisation. #ESCCongress #ESCGuidelines
“ASCEND is the largest & longest-duration of omega-3 fatty acid supplements ever. In this study we demonstrated no effect on the primary outcome of serious vascular events & no effect on cancer or total all-cause mortality" - Louise Bowman, MD #ESCCongress bit.ly/2MP3ANP
The SCOT-HEART study reports that doing a CT scan in pts w/ chest pain reduces heart attack by 41%.
And NEJM publishes it
This, my friends, deserves serious critical appraisal>> medscape.com/viewarticle/901…
#ESCcongress
#CardioTwitter
#FOAMed
Thx to @AndrewFoy82
CardiacDevices retweeted
Intriguing!
DR. Rioufil-FUTURE Trial: No difference in Primary endpoint death, MI, stroke in FFR guided vs Angio guided strategy in stable angina. Interestingly high all cause death in FFR group driven by complex coronary anatomy! #ESCCongress
#Medtronic’s trials show #AdaptivCRT algorithm reduces #atrial #fibrillation episodes cardiovasculardevices.medica…
www-ncbi-nlm-nih-gov.proxy-u…
Catheter Ablation for Atrial Fibrillation with #Heart Failure.